| scholarly article | Q13442814 |
| P2093 | author name string | Sebastian Oltean | |
| Athina Mavrou | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing | Q24321530 | ||
| Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy | Q26825053 | ||
| Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies | Q27016629 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Alternative isoform regulation in human tissue transcriptomes | Q27861118 | ||
| Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer | Q28251240 | ||
| Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing | Q29547470 | ||
| Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. | Q33429309 | ||
| Nova regulates brain-specific splicing to shape the synapse | Q34436585 | ||
| Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma | Q34447216 | ||
| Alternative mRNA transcription, processing, and translation: insights from RNA sequencing | Q34461131 | ||
| SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice | Q34478749 | ||
| The spliceosome is a therapeutic vulnerability in MYC-driven cancer | Q34492012 | ||
| Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro | Q34510663 | ||
| Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy | Q35221624 | ||
| Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant | Q35408783 | ||
| Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma | Q35833169 | ||
| Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | Q36058291 | ||
| Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy | Q36089148 | ||
| Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion | Q36577277 | ||
| Novel therapies for the treatment of advanced prostate cancer | Q36665708 | ||
| VEGF-A splicing: the key to anti-angiogenic therapeutics? | Q37035757 | ||
| SRPK1 Dissimilarly Impacts on the Growth, Metastasis, Chemosensitivity and Angiogenesis of Glioma in Normoxic and Hypoxic Conditions | Q37347529 | ||
| Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches | Q37537958 | ||
| Angiogenesis and anti-angiogenic therapy in prostate cancer. | Q38078609 | ||
| Hallmarks of alternative splicing in cancer | Q38171229 | ||
| The alternative splicing side of cancer. | Q38198391 | ||
| MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis | Q38299040 | ||
| Antiangiogenic therapy in oncology: current status and future directions | Q38725587 | ||
| The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas | Q38861204 | ||
| WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing | Q39427761 | ||
| An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition | Q39667327 | ||
| Modulators of alternative splicing as novel therapeutics in cancer | Q41904460 | ||
| Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study | Q43566256 | ||
| VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma | Q44068637 | ||
| SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. | Q44206065 | ||
| RBM24 is a major regulator of muscle-specific alternative splicing | Q51049428 | ||
| Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer | Q60156367 | ||
| Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas | Q79856279 | ||
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| alternative mRNA splicing, via spliceosome | Q21114084 | ||
| P304 | page(s) | 276-281 | |
| P577 | publication date | 2016-03-16 | |
| P1433 | published in | Pharmacological Research | Q15724622 |
| P1476 | title | SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing | |
| P478 | volume | 107 |
| Q45056589 | Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells |
| Q39223617 | RNA splicing and splicing regulator changes in prostate cancer pathology |
| Q57467861 | Role of alternative splicing of VEGF-A in the development of atherosclerosis |
| Q61450687 | SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway |
| Q60300790 | SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4 |
| Q42365311 | Serine-arginine protein kinase 1 (SRPK1) is elevated in gastric cancer and plays oncogenic functions |
| Q92446657 | Targeting Angiogenesis in Prostate Cancer |
| Q55128284 | Targeting Splicing in Prostate Cancer. |
Search more.